Raymond James raises Corpay stock price target on growth outlook By Investing.com

Raymond James raised Corpay’s price target to $390 from $361 and reiterated an Outperform rating, with the new target roughly matching InvestingPro fair value of $390.21 versus the current share price of $331. The firm sees modest upside to Q1 revenue and EPS, and lifted fiscal 2026 estimates slightly despite a $75 million revenue hit from the PaybyPhone divestiture, which it expects to be EPS-neutral. Corpay is also guiding to 10% organic revenue growth in 2026 and is trading at about 11x 2027 estimated EPS.

Analysis

CPAY is getting the kind of estimate reset that typically matters more than the headline target raise: the market is being told the divestiture is non-dilutive to earnings while narrowing the business mix toward higher-quality, more recurring corporate payments revenue. That matters because the stock’s multiple is increasingly being justified by mid-teens organic growth rather than legacy asset breadth, so the key question is whether the post-divestiture mix improves durability enough to support a higher terminal multiple, not just near-term EPS. If the company executes into the May earnings and segment update, the setup could force incremental buyers to chase a name that still screens at a discount to the implied growth profile.

The second-order effect is that fuel price exposure is less about direction and more about forecast convexity. If spreads truly absorb most of the first-quarter fuel move, then the market may be underestimating how much this business can self-hedge through its pricing model and spread mechanics, which reduces earnings volatility and supports a quality premium. The counterpoint is that FX and any slowdown in corporate spending could offset that stability quickly; the short-duration risk is not the divestiture but whether organic payments growth can stay above the market’s current mid-single-digit skepticism into the next two reporting cycles.

Consensus appears to be converging upward, but not fully underwriting the compounding effect of sustained organic growth plus a cleaner portfolio. The stock can still rerate if investors decide the 2027 EPS multiple is too low for a business with this margin structure and visible growth, especially ahead of the May 13 segment presentation, which is a likely catalyst for multiple expansion. The contrarian concern is that once the obvious estimate uplift is reflected, upside may depend on a second leg of revisions from payments momentum; absent that, the move could stall into the high-$300s.

Key Decisions for Investors

• Long CPAY into the May 6 earnings / May 13 Corporate Payments presentation window; target a 6-10% rerating if management confirms mid-teens organic growth and clean divestiture offsets, with a stop below the pre-earnings range if growth commentary softens.
• Buy CPAY June or September call spreads to express upside through the catalyst while limiting premium decay; structure for a move toward the low-$360s to high-$380s where consensus revisions and multiple expansion should collide.
• Pair trade: long CPAY / short a lower-quality payments or fintech proxy with more cyclicality and less pricing power if you want to isolate idiosyncratic execution; the thesis is CPAY deserves a premium for growth durability and margin resilience.
• If CPAY rallies sharply into the segment presentation without fresh guidance upside, take partial profits; the near-term re-rate is likely front-loaded and the second leg needs evidence, not narrative.
• For risk managers, watch FX-sensitive exposure and corporate spending data over the next 1-2 quarters; if macro weakens, trim exposure because the current setup assumes organic growth remains the dominant driver.